Celiprolol is an oral beta-1 adrenoceptor antagonist with partial beta-2 agonist activity proposed for the prevention of complications of vascular Ehlers-Danlos syndrome (EDS). Celiprolol has antihypertensive and antianginal properties, in addition to influencing vascular tone and smooth muscle. Celiprolol is believed to provide clinical benefit for people with vascular EDS by promoting normal collagen synthesis in the blood vessels, and by shifting the pressure load away from the vessels most prone to dissection and rupture.
If you have a Hayes login, click here to view the full report on the Knowledge Center.